VGA039 is a monoclonal antibody therapy with a novel mechanism of action that regulates Protein S, a key component in bringing balance to the blood clotting process. VGA039 has the potential to be a universal hemostatic therapy that can treat numerous bleeding disorders, starting with von Willebrand disease (VWD). As a subcutaneously self-administered antibody therapy with convenient dosing, VGA039 has the potential to significantly reduce the treatment burden for patients.
Company Details
- Industry
- Biotechnology
- Website
- https://vega-therapeutics.com/+
Vega Therapeutics Questions
Vega Therapeutics's website is https://vega-therapeutics.com/+
Vega Therapeutics's LinkedIn profile is https://www.linkedin.com/company/vega-therapeutics
Vega Therapeutics's industry is
Biotechnology
Vega Therapeutics's top competitors are
Kyverna Therapeutics,
Electra Therapeutics,
Star Therapeutics,
Neurogene Inc.,
Denali Therapeutics,
Latigo Biotherapeutics, Inc.,
Neuron23,
Levo Therapeutics,
Monopar Therapeutics Inc.,
Apollo Therapeutics.
Vega Therapeutics's categories are Biotechnology
